After-Hours Stock Movers 08/23: (CARA) (PANW) (BXC) Higher; (TBPH) (MARK) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Palo Alto Networks (PANW) PT Raised to $500 at Piper Sandler
August 24, 2021 8:48 AM EDTPiper Sandler analyst Rob Owens raised the price target on Palo Alto Networks (NYSE: PANW) to $500.00 (from $450.00) while maintaining an Overweight rating following results.
The analyst commented, "Highlights include billings and revenue acceleration, the first quarter ever of $2B+ bookings, and impressive... More
Palo Alto Networks (PANW) PT Raised to $509 at BTIG
August 24, 2021 7:21 AM EDTBTIG analyst Gray Powerll raised the price target on Palo Alto Networks (NYSE: PANW) to $509.00 (from $460.00) while maintaining a Buy rating.
... MorePalo Alto Networks (PANW) PT Raised to $475 at Cowen
August 24, 2021 6:51 AM EDTCowen analyst Shaul Eyal raised the price target on Palo Alto Networks (NYSE: PANW) to $475.00 (from $425.00) while maintaining an Outperform rating.
The analyst commented, "PANW's better than expected results and improved guidance should alleviate recent investors' concerns about potential margin erosion, mgnt shuffle, and... More
Theravance Biopharma (TBPH) PT Lowered to $18 at Needham & Company
August 24, 2021 6:24 AM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $18.00 (from $32.00) while maintaining a Buy rating.
The analyst commented, "TBPH announced yesterday the izencitinib Ph2b RHEA trial in Ulcerative Colitis (UC) failed to demonstrate efficacy vs... More



